Arcutis Biotherapeutics Beheer
Beheer criteriumcontroles 2/4
Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is $4.94M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $5.55M. The average tenure of the management team and the board of directors is 3 years and 4.5 years respectively.
Belangrijke informatie
Frank Watanabe
Algemeen directeur
US$4.9m
Totale compensatie
| Percentage CEO-salaris | 12.8% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 0.5% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 4.5yrs |
Recente managementupdates
Recent updates
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$5m | US$634k | -US$262m |
| Sep 30 2023 | n/a | n/a | -US$268m |
| Jun 30 2023 | n/a | n/a | -US$331m |
| Mar 31 2023 | n/a | n/a | -US$327m |
| Dec 31 2022 | US$5m | US$590k | -US$311m |
| Sep 30 2022 | n/a | n/a | -US$311m |
| Jun 30 2022 | n/a | n/a | -US$260m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$4m | US$525k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$3m | US$442k | -US$136m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$63m |
| Dec 31 2019 | US$1m | US$390k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$634k | US$327k | -US$19m |
Compensatie versus markt: Frank's total compensation ($USD4.94M) is above average for companies of similar size in the US market ($USD3.24M).
Compensatie versus inkomsten: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Watanabe (56 yo)
8.8yrs
Tenure
US$4,935,266
Compensatie
Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.8yrs | US$4.94m | 0.55% $ 5.6m | |
| Co-Founder & Independent Director | no data | US$153.74k | 0.77% $ 7.8m | |
| Senior VP & Chief Medical Officer | 4.3yrs | US$1.67m | 0.017% $ 167.7k | |
| Senior VP & Chief Commercial Officer | 1.2yrs | US$2.03m | geen gegevens | |
| Senior VP & Chief Financial Officer | less than a year | geen gegevens | 0.041% $ 419.4k | |
| Chief Digital & Technology Officer | 3.1yrs | geen gegevens | geen gegevens | |
| Vice President of Finance & Investor Relations | no data | geen gegevens | geen gegevens | |
| VP and Chief Compliance Officer & Privacy Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Senior VP | 2.8yrs | US$5.14m | 0.022% $ 227.8k | |
| Head of Corporate Communications | 3.3yrs | geen gegevens | geen gegevens | |
| Head of Marketing & Market Access | 1.2yrs | geen gegevens | geen gegevens | |
| Vice President of Sales | 1.8yrs | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: ARQT's management team is considered experienced (3 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.8yrs | US$4.94m | 0.55% $ 5.6m | |
| Co-Founder & Independent Director | 8.6yrs | US$153.74k | 0.77% $ 7.8m | |
| Independent Chairman of the Board | 8.6yrs | US$181.24k | 0.028% $ 280.7k | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Independent Director | 4yrs | US$148.74k | 0.0074% $ 75.3k | |
| Independent Director | 4.5yrs | US$148.74k | 0.0074% $ 75.3k | |
| Director | 4.3yrs | US$144.24k | 0.15% $ 1.5m | |
| Independent Director | 3.4yrs | US$163.74k | 0.0077% $ 77.9k | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren bestuur: ARQT's board of directors are considered experienced (4.5 years average tenure).